<DOC>
	<DOCNO>NCT00001737</DOCNO>
	<brief_summary>This study evaluate safety effectiveness sustained-release cyclosporin implant treat uveitis , sight-threatening eye inflammation cause immune system abnormality . Previous study human show , take mouth , drug cyclosporin effective treat chronic uveitis . Uveitis may require long-term treatment potent immune-suppressing drug , cyclosporin , cyclophosphamide , methotrexate , azathioprine steroid . Taken systemically ( mouth injection ) , however , drug serious damage kidney , liver lung , raise blood pressure lower blood cell count . Because , patient use medicine . This small pilot study evaluate safety , extent effectiveness , cyclosporin deliver directly eye , try prevent harmful side effect . In animal study , sustained-release cyclosporin implant cause severe side effect see systemic use drug . Some animal develop opacity lens slow retinal response , reverse drug stop . Earlier animal study cyclosporin inject directly eye reduce inflammation produce experimentally . Patients uveitis active inflammation poor vision eligible participate study . Patients randomly assign one two treatment group . One group receive 1-mg implant release 0.8 micrograms drug day ; second group receive 2-mg implant delivers 1.4 microgram drug day . Before surgery , patient medical history , basic physical examination , complete eye examination , include special test call electroretinogram fluorescein angiography . An electroretinogram measure electrical response generate retina back eye . Fluorescein angiography use special camera photograph retina , show condition blood vessel eye . The surgical procedure place implant take 1.5 hour may do either local general anesthesia . Patients stay hospital overnight . After discharge hospital , return follow-up visit 1 2 week surgery , month 6 month , every 3 month implant deplete drug remove . During follow-up visit , eye examination repeat evaluate effect implant eye . Repeat blood test measure amount cyclosporin blood drug 's effect kidney . When implant run drug ( 2 3 year ) , may remove left place .</brief_summary>
	<brief_title>Cyclosporin Implant Treat Uveitis</brief_title>
	<detailed_description>Sight threaten uveitis may require long term use systemic immunosuppressant . In patient , aggressive systemic immunosuppressive therapy fail control inflammation lead serious side effect . Oral Cyclosporin A ( CsA ) show several human trial effective treat chronic uveitis . This pilot study ass safety , extent efficacy , novel intraocular CsA release implant patient active inflammation poor visual acuity one eye despite immunosuppressant therapy . Patients randomly assign receive one eye 1 2 mg CsA implant release either 0.8 microgram per day 1.4 microgram per day respectively . The main purpose study assess safety CsA implant . Secondary outcome include change baseline ocular inflammation , visual acuity , need concomitant anti-inflammatory medication .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>INCLUSION CRITERIA : Age range : 15 older . Active noninfectious intermediate , posterior panuveitis present least 6 month despite systemic immunosupressive therapy include least 20 mg oral prednisone use another immunosuppressive agent . Visual acuity bad 20/80 ( 55 letter ) good 5/200 ( 4 letter ) eye receive CsA implant , good 20/80 ( 54 letter ) nonstudy eye . Bilateral unilateral uveitis active inflammation one eye ( eye implant ) . Patients may continue systemic immunosuppressant exception systemic CsA . Patients may take great 1 drop topical steroid four time day eye implant maintenance anterior segment inflammation 1 month postoperatively . Recordable electroretinogram ( ERG ) . Willingness ability , assistance care giver , necessary , comply treatment followup procedure . The ability understand sign inform consent form must obtain prior treatment . Negative serum pregnancy test ( female childbearing potential ) . Normal serum creatinine ( males 0.9 1.4 mg/dL , females 0.7 1.3 mg/dL ) . No current past history retinal detachment . EXCLUSION CRITERIA : Current past history retinal detachment . Pregnant lactating patient patient potential conception unless use effective contraception . Fertile male must use effective contraception . Contraception would longer mandatory participation study three month postoperatively assume ( 1 ) negligible CsA absorption , ( 2 ) patient take medication may affect develop fetus spermatogenesis . Patients receive therapy within previous one week nephrotoxic drug . Patients know allergy CsA . Patients receive current therapy CsA . Patients need systemic CsA seven day prior implant surgery . Patients may continue immunosuppressive therapy need control inflammation contralateral ( nonstudy ) eye provide inflammation currently active .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2004</verification_date>
	<keyword>Eye</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Therapy</keyword>
	<keyword>Vitreous</keyword>
	<keyword>Uveitis</keyword>
</DOC>